local
White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
Summary by The El Paso Editorial Desk Ashleigh Fields and The Hill , as published by KTSM 9 News (NBC)
· June 24, 2026
· 1 min read
Photo: KTSM 9 News (NBC) · view original
Story provenance No corrections
Summary created by The El Paso Editorial Desk — automated, rule-governed Byline on source page Ashleigh Fields and The Hill, as published by KTSM 9 News (NBC) Original story Read at the source Source published Jun 24, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key takeaway Further details on this matter are available from KTSM 9 News, including information on speculation surrounding a high-profile individual's potential access to the drug.
A recent development has sparked interest regarding access to an experimental obesity drug. The drug in question, retatrutide, is manufactured by Eli Lilly and has not received FDA approval. It is known that one individual has gained access to the prescription through a special program.
This program is designed to approve experimental treatments for patients with life-threatening illnesses. Further details on this matter are available from KTSM 9 News, including information on speculation surrounding a high-profile individual's potential access to the drug.
Why this matters
Local news anchors readers in their community — the people, places, and decisions that shape day-to-day life. The El Paso covers these stories because national outlets often won't.
About this story
As published by KTSM 9 News (NBC) . The El Paso surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit KTSM 9 News (NBC) . Have a tip or correction? Contact our newsroom .
Category: local Published: June 24, 2026 Source: KTSM 9 News (NBC) Reading time: 1 min
Frequently asked about this story
What is this story about? A recent development has sparked interest regarding access to an experimental obesity drug. The drug in question, retatrutide, is manufactured by Eli Lilly and has not received FDA approval. It is…
When was this published? This article was first published on June 24, 2026 by KTSM 9 News (NBC) and curated for The El Paso readers.
Who reported this story? This story was reported by Ashleigh Fields and The Hill at KTSM 9 News (NBC). To learn more about how The El Paso selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from The El Paso, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter
